Safety profile of empagliflozin in clinical practice: A scoping review of real-world evidence

Empagliflozin, a sodium–glucose cotransporter-2 inhibitor, is widely prescribed for Type 2 diabetes mellitus and heart failure. Post-marketing surveillance plays a crucial role in evaluating its real-world safety beyond clinical trials. This scoping review aimed to synthesize available evidence on the post-marketing safety of empagliflozin, focusing on key adverse outcomes and surveillance approaches. A systematic search of PubMed and regulatory sources was conducted for studies published betwee